Brand leaders in RA will lose market share, predict rheumatologists
December 19, 2013 | Biologics, rheumatoid arthritis
Rheumatologists believe that the current market for biologic treatments in Rheumatoid Arthritis (RA) will see key changes in the next three years.
Rheumatologists believe that the current market for biologic treatments in Rheumatoid Arthritis (RA) will see key changes in the next three years.In a recent study, physicians predicted that current market leaders Enbrel (etanercept) and Humira (adalimumab) will continue to lose market share to newer biologics such as RoActemra (tocilizumab), Orencia (abatacept) and Simponi (golimumab) and may experience strong competition from biosimilar agents and pipeline products with novel mechanisms of action, including small molecules.The survey, which was conducted by global healthcare specialists Research Partnershipamongst European rheumatologists, asked physicians to give their opinions on the current and future RA treatment landscape. Across the EU, physicians believe that biologic usage will increase by an average of 8% over the next three years. However, they also expect that use of traditional anti-TNFs such as Enbrel and Humira will decrease by 6% over the same period and pipeline products are expected to capture a larger pool of patients in the double digits.
Enbrel and Humira currently dominate the RA biologics market thanks to strong performances on key product attributes including long-term efficacy and safety. They achieve high scores on overall satisfaction and likelihood to recommend and are firmly anchored as physicians’ preferred biologic treatments. In addition, these brands stand out from other agents on personal experience, making it difficult for newer products to threaten their established position.
Newer biologics have traditionally dominated the 2nd line+ market and, while they still can’t compete closely with the more established anti-TNFs in the larger 1st line market, they have been making steady gains in the segment as physicians look to expand their armamentarium.
Physicians were also surveyed on their unprompted awareness of pipeline products. JAK-inhibitors were the most commonly mentioned class, with Xeljanz the most frequently cited product.
Laurent Chanroux, Associate Director of Therapy Watch comments, “the next few years will be an exciting time for the treatment of RA. With an ageing population, the RA market looks certain to continue to grow in the foreseeable future. However, the current biologics market is crowded and reaching maturity, with several key agents launched more than 10 years ago. The growing use of non TNF-inhibitor biologics, along with the gradual launch of biosimilars and new small molecules, has the potential to dramatically change the market landscape in the medium to long term. The EMA’s refusal to grant a marketing authorisation for Xeljanz was disappointing for Pfizer, however, the drug is said to be performing in line with company predictions outside of the EU, with sales of $68m in the first nine months of 2013. Moreover, while Pfizer expects the launch of the drug in Europe to be delayed by several years, a number of other novel small molecules are being investigated by competitors and may reach the market before then.”
Therapy Watch RA is a regular syndicated study conducted amongst 200 physicians in Europe every month and is a service of global healthcare specialist Research Partnership. The study looks at current treatment programmes, product choice selection, patient profiles, market share and switching behaviour. The RA Perceptions survey was conducted alongside the regular tracking study amongst a panel of 208 rheumatologists in France, Germany, Italy, Spain and the UK in June/July 2013. The full report is now available to purchase for £10k/€12k/$16k.The comprehensive report, RA Perceptions, has been published and is now available to purchase. Click here to find out more.
We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we use our expertise and experience to deliver intelligent, tailor-made solutions. We provide strategic recommendations that go beyond research, helping our clients to answer their fundamental business challenges. Find out more at http://bit.ly/1KntpKd
This content was provided by Research Partnership
Company Details
Latest Content from Research Partnership
News: Research Partnership is listed in the Alantra Pharma Fast 50 annual report
The best performing privately-owned UK pharmaceutical businesses were revealed earlier this month with the publication of Pharma Times’ Alantra Pharma Fast 50 annual report.Read more about this report here
Event: Blending data science and market research at the Data Analytics & Insight conference
Last month Analytics Director Misti Paul attended the Data Analytics & Insight Conference. In our latest blog post she reflects on the presentations that were given and what lessons can be...
Presentation: Optimize your digital assets with UX research
US Director Liza Pliss recently presented the paper 'Optimize your digital assets with UX research' at the PMR Conference in New Jersey, USA. Don't worry if you missed it though,...
Report: Living With Rheumatoid Arthritis 2019 reports now available to purchase
We have published new Living with Rheumatoid Arthritis reports in 5EU, Japan and Canada. The reports consist of 30-minute quantitative online and qualitative telephone interviews with RA patients. Read more on...
Infographic: Rheumatoid arthritis (RA)
An overview of the RA biologic patientOur RA market snapshot offers an introduction to the real world patient data collected by our Therapy Watch RA study. The snapshot looks at...
Webcast: Navigating new frontiers: Ways to find space in the future RA market
In partnership with pharmaphorumView the webcast »The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market.Although there are only...
Live Webinar: China in the fast lane: How to play and win in the world’s hottest emerging market
Tuesday 16th April 2019 10:00 EST/ 15:00 GMT / 16:00 CEST
Webcast: Poker face revealed: Using facial analysis to uncover deeper levels of emotional insight
In the first part of our series covering market research innovations which have value in healthcare, we demonstrate how we've been using facial analysis to delve further into respondents' reactions...
Report: Living with RA (EU, Japan and Canada) 2019 reports
Research Partnership launches new patient Living with Rheumatoid Arthritis (EU & Japan) 2019 report.r Living with Rheumatoid Arthritis (RA) is a quantitative study conducted online amongst 390 patients diagnosed with RA in...
News: Therapy Watch launches a new wave of EU tracking in Psoriasis (PsO)
A panel of 40 dermatologists in each of the major EU markets reports on patients on advanced therapies including biologics and small molecule therapies every quarter. In addition from Q1...